Drugs / Para-aminohippuric Acid
Para-aminohippuric Acid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01426529 | Oct 2010 → Oct 2026 expected | hypertensive disorder | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01702688 Background | Jul 2012 → ? | essential hypertension | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Para-aminohippuric Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01426529 ↗ |
| Modality | Diagnostic / imaging agent | “Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF).” NCT01426529 ↗ |